Generation Bio Co

GBIO

Company Profile

  • Business description

    Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

  • Contact

    301 Binney Street
    CambridgeMA02142
    USA

    T: +1 617 655-7500

    https://www.generationbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    115

Stocks News & Analysis

stocks

Westpac earnings: Tech overhaul is costly but not hurting lending and deposit growth

Our view after latest earnings report.
stocks

Future Focus: Are franking credits ‘free alpha’?

There’s always an opportunity cost.
stocks

Berkshire Hathaway earnings: Cash balances hit $358 billion on mostly solid results across the firm

We think Berkshire Hathaway stock is moderately undervalued.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,174.0015.500.17%
CAC 408,109.7911.28-0.14%
DAX 4024,132.41174.110.73%
Dow JONES (US)47,336.68226.19-0.48%
FTSE 1009,701.3715.88-0.16%
HKSE26,158.36251.710.97%
NASDAQ23,834.72109.770.46%
Nikkei 22552,411.341,085.732.12%
NZX 50 Index13,586.2329.930.22%
S&P 5006,851.9711.770.17%
S&P/ASX 2008,882.7024.100.27%
SSE Composite Index3,976.5221.730.55%

Market Movers